Your session is about to expire
← Back to Search
Heparin for Heart Disease
Phase 3
Recruiting
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnostic cardiac catheterization
Be older than 18 years old
Must not have
Patients requiring anticoagulation
Prior surgery close to the access site
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 hours
Awards & highlights
Pivotal Trial
All Individual Drugs Already Approved
Approved for 20 Other Conditions
Summary
This trial will study whether different doses of anticoagulants given to patients during cardiac catheterization affects the rate of thrombotic complications.
Who is the study for?
This trial is for patients needing diagnostic cardiac catheterization using a small size sheath and with good ulno-palmar blood flow. It's not suitable for those with abnormal blood flow in this area, previous radial artery clotting, surgery near the access site, urgent catheterization needs, heparin allergies or history of Heparin-Induced Thrombocytopenia (HIT), or if they already need anticoagulants.
What is being tested?
The study is testing the effects of no anticoagulant versus low and high doses of heparin during cardiac catheterization. Patients will be randomly assigned to one of these three groups to compare outcomes.
What are the potential side effects?
Potential side effects from heparin may include bleeding complications, allergic reactions, and possibly thrombocytopenia (a decrease in platelets which can affect clotting). The placebo group should not experience these side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have had a heart catheterization test.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I need medication to prevent blood clots.
Select...
I have had surgery near the area where they plan to access my body for the trial.
Select...
I have had an urgent heart catheterization procedure.
Select...
I have had a blood clot in the artery of my wrist before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
hematoma
radial artery occlusion
Secondary study objectives
access site bleeding
access site complications
non access site bleeding
+2 moreAwards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: Low dose heparinActive Control1 Intervention
heparin (25 IU/Kg -maximal dose 3,000 IU)
Group II: High dose heparinActive Control1 Intervention
heparin 50 IU/kg -maximal dose 5,000 IU
Group III: PlaceboPlacebo Group1 Intervention
Normal saline 0.9%.
Find a Location
Who is running the clinical trial?
Lawson Health Research InstituteLead Sponsor
683 Previous Clinical Trials
427,820 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I need medication to prevent blood clots.A small-sized tube is used.My hand's blood flow is normal.I have had surgery near the area where they plan to access my body for the trial.I have had a heart catheterization test.I have had an urgent heart catheterization procedure.You have abnormal blood flow in your hands.I have had a blood clot in the artery of my wrist before.You have had heparin-induced thrombocytopenia or are allergic to heparin.
Research Study Groups:
This trial has the following groups:- Group 1: Low dose heparin
- Group 2: High dose heparin
- Group 3: Placebo
Awards:
This trial has 3 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.